ArticleJournal of traditional and complementary medicine2026
Electroacupuncture promotes the repair of lacrimal glands damage in dry-eye animal models by modulating the BDNF/CREB signaling pathway.
Article in Journal of traditional and complementary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Dry eye disease (DED) is an eye disorder with global prevalence. Its treatment using electroacupuncture (EA) has shown exceptional clinical efficacy. This study aimed to examine the effectiveness of EA in treating DED and explore its underlying molecular mechanisms. Experimental procedure: A rabbit model of aqueous-deficient dry eye was established by subcutaneous injection of scopolamine hydrobromide. The EA and EA plus K252a (EA + K252a) groups underwent EA treatment (20 Hz, 0.5 ms, and 1 mA) for 15 min per session. The sham acupuncture (SA) group received blunt-tipped needling. These interventions were performed once daily for 14 days. At day 28 of the experiment, the role of the BDNF/CREB pathway was examined by administration of the TrkB antagonist K252a. K252a was bilaterally injected into the lacrimal glands (LGs) in both the K252a and EA + K252a groups. Outcome measures included tear film break-up time (BUT), corneal fluorescein staining (FL), Schirmer I tear test (SIT), and pathological changes in the ocular surface and LGs. The levels of brain-derived neurotrophic factor (BDNF), tyrosine kinase receptor B (TrkB), phospho-phosphatidylinositol 3-kinase (p-PI3K), phospho-protein kinase B (p-AKT), cyclic adenosine monophosphate response element-binding protein (CREB), and phospho-cyclic adenosine monophosphate response element-binding protein (p-CREB) were assessed. Results and conclusion: Experimental results showed that EA facilitates the restoration of damaged LGs, extends BUT, decreases FL, and enhances SIT by regulating the proteins involved in the BDNF/CREB pathway. Consequently, these improvements effectively alleviate the symptoms associated with DED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.